Our Pipeline

Boehringer Ingelheim is taking on cancer through a dedicated commitment to delivering first-in-class cancer cell-directed therapies, innovative immuno-oncology strategies and smart combination approaches, which can transform the lives of patients.

Filter by:
Compound and target LATEST DEVELOPMENT PHASE (AS OF JULY 2021)
Phase I Phase II Phase III
Cancer cell-directed and immuno-oncology therapies

CD137/FAP bispecific agonist antibody

In preparation
P In Preparation

VSV-GP

In preparation
P In Preparation
Combination Approaches

VEGF/Ang2 inhibitor (BI 836880) + ezabenlimab (BI 754091)

Solid tumors
1 Phase I
NSCLC
1 Phase I
Gastrointestinal cancers
2 Phase II
Solid tumors
2 Phase II

SIRP Alpha antagonist (BI 765063) + ezabenlimab (BI 754091)

Solid tumors
1 Phase I

STING agonist (BI 1387446) + ezabenlimab (BI 754091)

Solid tumors
1 Phase I

DLL3/CD3 bispecific antibody (BI 764532) + ezabenlimab (BI 754091)

NETs
1 Phase I
SCLC
1 Phase I

SOS1::KRAS inhibitor (BI 1701963) + MAPK pathway inhibitor (tramatenib)

Solid tumors
1 Phase I

SOS1::KRAS inhibitor (BI 1701963) + irinotecan

CRC
1 Phase I

MDM2-p53 antagonist (BI 907828) + ezabenlimab (BI 754091)

Solid tumors
1 Phase I

B7-H6/CD3 antibody (BI 765049) + ezabenlimab (BI 754091)

Solid tumors
1 Phase I

MEK inhibitor (BI 3011441) + SOS1::KRAS inhibitor (BI 1701963)

Solid tumors
1 Phase I

References

1

ClinicalTrials.gov. NCT03099174. https://clinicaltrials.gov/ct2/show/NCT03099174 (Accessed: July 2021).

2

ClinicalTrials.gov. NCT02123823. https://clinicaltrials.gov/ct2/show/NCT02123823 (Accessed: July 2021).

3

ClinicalTrials.gov. NCT03659136. https://clinicaltrials.gov/ct2/show/NCT03659136 (Accessed: July 2021).

4

ClinicalTrials.gov. NCT02674152. https://clinicaltrials.gov/ct2/show/NCT02674152 (Accessed: July 2021).

5

ClinicalTrials.gov. NCT02689505. https://clinicaltrials.gov/ct2/show/NCT02689505 (Accessed: July 2021).

6

ClinicalTrials.gov. NCT03972150. https://clinicaltrials.gov/ct2/show/NCT03972150 (Accessed: July 2021).

7

ClinicalTrials.gov. NCT02952248. http://clinicaltrials.gov/ct2/show/NCT02952248 (Accessed: July 2021).

8

ClinicalTrials.gov. NCT03449381. https://clinicaltrials.gov/ct2/show/NCT03449381 (Accessed: July 2021).

9

ClinicalTrials.gov. NCT03604445. https://clinicaltrials.gov/ct2/show/NCT03604445 (Accessed: July 2021).

10

ClinicalTrials.gov. NCT03990233. https://clinicaltrials.gov/ct2/show/NCT03990233 (Accessed: July 2021).

11

ClinicalTrials.gov. NCT04111458. https://clinicaltrials.gov/ct2/show/NCT04111458 (Accessed: July 2021).

12

ClinicalTrials.gov. NCT04627142. https://clinicaltrials.gov/ct2/show/NCT04627142 (Accessed: July 2021).

13

ClinicalTrials.gov. NCT04137289. https://clinicaltrials.gov/ct2/show/NCT04137289 (Accessed: July 2021).

14

ClinicalTrials.gov. NCT04147234. https://clinicaltrials.gov/ct2/show/NCT04147234 (Accessed: July 2021).

15

ClinicalTrials.gov. NCT04046445. https://clinicaltrials.gov/ct2/show/NCT04046445 (Accessed: July 2021). 

16

ClinicalTrials.gov. NCT04429087. https://clinicaltrials.gov/ct2/show/NCT04429087 (Accessed: July 2021). 

17

ClinicalTrials.gov. NCT04742556. http://clinicaltrials.gov/ct2/show/NCT04742556 (Accessed: July 2021). 

18

ClinicalTrials.gov. NCT04441099. http://clinicaltrials.gov/ct2/show/NCT04441099 (Accessed: July 2021).

19

ClinicalTrials.gov. NCT04752215. https://clinicaltrials.gov/ct2/show/NCT04752215 (Accessed: July 2021). 

20

ClinicalTrials.gov. NCT04886804. https://clinicaltrials.gov/ct2/show/NCT04886804 (Accessed: July 2021). 

21

ClinicalTrials.gov. NCT03468426. https://clinicaltrials.gov/ct2/show/NCT03468426 (Accessed: July 2021).

22

ClinicalTrials.gov. NCT03697304. https://clinicaltrials.gov/ct2/show/NCT03697304 (Accessed: July 2021).

23

ClinicalTrials.gov. NCT03964233. https://clinicaltrials.gov/ct2/show/NCT03964233 (Accessed: July 2021). 

24

ClinicalTrials.gov. NCT04835714. https://clinicaltrials.gov/ct2/show/NCT04835714 (Accessed: July 2021).

Pipeline compounds shown here are under pre-clinical and/or clinical investigation, and have not been approved. Their safety and efficacy have not been established.

 

ADC, antibody-drug conjugate; Ang2, angiopoietin 2; CD, cluster of differentiation; CDH17, cell anchor cadherin 17; CRC, colorectal cancer; DLL3, Delta-like 3; EGFR, epidermal growth factor receptor; FAP, fibroblast activation protein; GI, gastrointestinal; GP, glycoprotein; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma; LRP, lipoprotein receptor-related protein; MDM2, murine double minute 2 protein; MEK, mitogen-activated extracellular signal regulated kinase; NET, neuroendocrine tumor; NSCLC, non-small-cell lung cancer; ROR1, receptor tyrosine kinase-like orphan receptor 1; SCLC, small-cell lung cancer; SIRPα, signal-regulatory protein alpha; SOS1, Son of sevenless homolog 1; STING, small molecule agonist of the stimulator of interferon genes; TRAILR2, tumor necrosis factor-related apoptosis-inducing ligand receptor 2; VEGF, vascular endothelial growth factor; VSV, vesicular stomatitis virus.

 

© 2021 Boehringer Ingelheim International GmbH. All rights reserved.

 

Page last updated: July 2021